Published in Clin Transpl on January 01, 1993
Causes of late mortality in pediatric liver transplant recipients. Ann Surg (1998) 1.08
Actively acquired tolerance of foreign cells. Nature (1953) 19.82
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
A highly sensitive method to assay FK-506 levels in plasma. Transplant Proc (1987) 8.45
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature (1984) 4.26
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med (1977) 3.48
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst (1955) 2.16
Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc (1991) 1.69
Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. Transplantation (1992) 1.68
Neurologic complications of FK 506. Transplant Proc (1991) 1.34
Assay of FK 506 in plasma. Transplant Proc (1990) 1.32
Infections with FK 506 immunosuppression: preliminary results with primary therapy. Transplant Proc (1990) 1.30
Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings. Transplant Proc (1990) 1.23
Adverse effects of FK 506 overdosage after liver transplantation. Transplant Proc (1993) 1.18
Disease gravity and urgency of need as guidelines for liver allocation. Hepatology (1994) 1.16
Liver transplantation under cyclosporine: a decade of experience. Transplant Proc (1991) 1.07
Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. Transplant Proc (1991) 1.06
FK 506 dosage in human organ transplantation. Transplant Proc (1990) 0.99
FK506 and pregnancy in liver transplant patients. Transplantation (1993) 0.90
Summary of the First International FK 506 Congress: perspectives and prospects. Transplant Proc (1991) 0.89
Human liver xenotransplantation. Xeno (1993) 0.81
Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. Transplant Proc (1991) 0.80
Frequency and severity of HCV infection following orthotopic liver transplantation. Effect of donor and recipient serology for HCV using a second generation ELISA test. J Hepatol (1993) 0.78
Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. Transplant Proc (1991) 0.77
Infectious complications of pediatric liver transplantation under FK 506. Transplant Proc (1991) 0.76
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Racial discrimination in the allocation of distinction awards? Analysis of list of award holders by type of award, specialty and region. BMJ (1998) 12.93
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Kidney transplantation under FK 506. JAMA (1990) 7.45
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med (2001) 4.01
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Antitumor agents. 203. Carbazole alkaloid murrayaquinone A and related synthetic carbazolequinones as cytotoxic agents. J Nat Prod (2000) 3.62
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Implementation of a high-sensitivity Micro-Angiographic Fluoroscope (HS-MAF) for in-vivo endovascular image guided interventions (EIGI) and region-of-interest computed tomography (ROI-CT). Proc SPIE Int Soc Opt Eng (2008) 3.49
Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med (1992) 3.42
Characterization and localization of the even-skipped protein of Drosophila. EMBO J (1987) 3.29
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Increased expression of sialyl Lewisx antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res (1993) 2.39
Maternal feeding practices and beliefs and their relationships to overweight in early childhood. J Dev Behav Pediatr (2001) 2.39
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res (2001) 2.22
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J (2002) 2.19
Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology (1999) 2.15
Cardiovascular risk assessment of South Asians in a religious setting: a feasibility study. Int J Clin Pract (2011) 2.12
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
Delayed graft function in the kidney transplant. Am J Transplant (2011) 2.06
Reduction in radiation exposure during coronary angiography. Cathet Cardiovasc Diagn (1990) 2.03
Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. Thromb Haemost (2014) 2.02
Pathology of human intestinal transplantation. Gastroenterology (1996) 1.98
Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet (1995) 1.96
BCL-6 expression during B-cell activation. Blood (1996) 1.95
Logistics and technique for combined hepatic-intestinal retrieval. Ann Surg (1992) 1.85
Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83
The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83
Endotoxaemia, pulmonary complications, and thrombocytopenia in liver transplantation. Lancet (1989) 1.82
Corrective treatment and anatomic considerations for laparoscopic cholecystectomy injuries. J Am Coll Surg (1994) 1.81
A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant (2009) 1.81
Monitoring and treatment of intestinal allograft rejection in humans. Transplant Proc (1993) 1.78
Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc (1991) 1.77
Infections in adult liver transplant patients under FK 506 immunosuppression. Transplant Proc (1991) 1.75
Molecular characterization of the zerknüllt region of the Antennapedia gene complex in Drosophila. Genes Dev (1987) 1.75
Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg (1988) 1.74
Characterization by deletion mutagenesis in vitro of the promoter region of ompF, a positively regulated gene of Escherichia coli. J Mol Biol (1984) 1.74
Small intestinal transplantation in humans with or without the colon. Transplantation (1994) 1.74
Investigating the thyroid nodule. BMJ (2009) 1.73
Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg (1998) 1.72
The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg (1996) 1.71
Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. Transplant Proc (1991) 1.69
A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation (1999) 1.62
Role of lipopolysaccharide and outer membrane protein of Escherichia coli K-12 in the receptor activity for bacteriophage T4. J Bacteriol (1978) 1.61
The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc (1991) 1.60
Renal cell carcinoma metastatic to the pancreas: a single-institution series and review of the literature. Urology (2000) 1.59
Accuracy and applicability of the revised WHO classification (2009) of dengue in children seen at a tertiary healthcare facility in northern India. Infection (2013) 1.59
Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation (1995) 1.59
Maternal regulation of zerknüllt: a homoeobox gene controlling differentiation of dorsal tissues in Drosophila. Nature (1988) 1.58
Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57
Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc (1990) 1.56
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
Ambiguous coronary angiography: clinical utility of intravascular ultrasound. Cathet Cardiovasc Diagn (1992) 1.54
Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. AJR Am J Roentgenol (2001) 1.54
Experimental transmission of Creutzfeldt-Jakob disease and related diseases to rodents. Neurology (1996) 1.54
Torsade de pointes during orthotopic liver transplantation. Anesth Analg (1998) 1.53
Expanding the donor kidney pool: utility of renal allografts procured in a setting of uncontrolled cardiac death. Am J Transplant (2006) 1.53
Morphological effects of coronary balloon angioplasty in vivo assessed by intravascular ultrasound imaging. Circulation (1992) 1.53
Hemophagocytic syndrome in five patients with Epstein-Barr virus negative B-cell lymphoma. Cancer (1998) 1.52
Concurrent dengue virus and Japanese encephalitis virus infection of the brain: is it co-infection or co-detection? Infection (2012) 1.52
Polymerase chain reaction vs. conventional diagnosis in fine needle aspirates of tuberculous lymph nodes. Acta Cytol (2001) 1.51
A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology (1992) 1.50
Moderate increase of mean daily temperature adversely affects fruit set of Lycopersicon esculentum by disrupting specific physiological processes in male reproductive development. Ann Bot (2006) 1.49
An analysis of early renal transplant protocol biopsies--the high incidence of subclinical tubulitis. Am J Transplant (2001) 1.48
The role of total parenteral nutrition in the management of patients with acute attacks of inflammatory bowel disease. J Clin Gastroenterol (1999) 1.48
Bacteriology of neonatal septicaemia in a tertiary care hospital of northern India. Indian J Med Microbiol (2007) 1.48
Converted laparoscopic colorectal surgery. Surg Endosc (2001) 1.48
Experimental infection studies of UK Culicoides species midges with bluetongue virus serotypes 8 and 9. Vet Rec (2008) 1.47
Ancestral origins and worldwide distribution of the PRNP 200K mutation causing familial Creutzfeldt-Jakob disease. Am J Hum Genet (1999) 1.46
Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation (1992) 1.45
Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int (1996) 1.45
Coronary artery fistula related to dilatation of totally occluded vessel. Clin Cardiol (1993) 1.44
Transversus abdominis plane block using the loss of resistance to air technique. Minerva Anestesiol (2012) 1.43